Role of TGF-β in a mouse model of high turnover renal osteodystrophy

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1141-1157

  Liu, Shiguang ^a   Song, Wenping ^a   Boulanger, Joseph H ^a   Tang, Wen ^a   Sabbagh, Yves ^a   Kelley, Brian ^a   Gotschall, Russell ^a   Ryan, Susan ^a   Phillips, Lucy ^a   Malley, Katie ^a   Cao, Xiaohong ^a   Xia, Tai He ^a   Zhen, Gehua ^b   Cao, Xu ^b   Ling, Hong ^a   Dechow, Paul C ^c   Bellido, Teresita M ^d,e   Ledbetter, Steven R ^a   Schiavi, Susan C ^a  

^a SANOFI   (France)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c BAYLOR COLLEGE OF DENTISTRY   (United States)

^d Department of Anatomy and Cell Biology Division of Endocrinology   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone turnover; chronic kidney disease; renal osteodystrophy; TGF

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; SMAD2 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; DIFFERENTIATION ANTIGEN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PEPTIDE; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE BIOPSY; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; MARKER GENE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL OSTEODYSTROPHY; TRABECULAR BONE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; RADIOGRAPHY; SPRAGUE DAWLEY RAT; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, DIFFERENTIATION; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; MALE; MICE; OSTEOCALCIN; OSTEOCLASTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RENAL OSTEODYSTROPHY; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; WNT SIGNALING PATHWAY; X-RAY MICROTOMOGRAPHY;

EID: 84899101883     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2120     Document Type: Article

References (70)

1. KDIGO CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009; (113): S1-130.
2. Jamal SA, West SL, Miller PD,. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int. 2012; 23 (4): 1191-8.
3. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995; 310 (6976): 358-63.
4. Moe SM, Radcliffe JS, White KE, et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011; 26 (11): 2672-81.
5. Wesseling-Perry K, Pereira RC, Tseng CH, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7 (1): 146-52.
6. Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27 (8): 1757-72.
7. Lobao R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004; 62 (6): 432-9.
8. Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME,. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res. 2010; 25 (3): 499-504.
9. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69 (11): 1945-53.
10. Malluche HH, Mawad H, Monier-Faugere MC,. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire ? Nephrol Dial Transplant. 2004; 19(Suppl 1):i 9-13.
11. Hruska KA, Mathew S, Lund RJ, Memon I, Saab G,. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009; 29 (2): 156-65.
12. Price PA, Faus SA, Williamson MK,. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21 (5): 817-24.
13. Price PA, June HH, Buckley JR, Williamson MK,. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21 (10): 1610-6.
14. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC,. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009; 75 (6): 617-25.
15. Gonzalez EA, Lund RJ, Martin KJ, et al. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int. 2002; 61 (4): 1322-31.
16. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM,. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109 (6): 697-711.
17. Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008; 19 (2): 405-12.
18. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA,. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol. 2007; 18 (1): 122-30.
19. Chertow GM, Burke SK, Raggi P,. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62 (1): 245-52.
20. Drueke TB,. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens. 2005; 14 (4): 343-9.
21. Andress DL,. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69 (1): 33-43.
22. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005; 20 (5): 764-72.
23. Stubbs JR, He N, Idiculla A, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res. 2012; 27 (1): 38-46.
24. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR, Zhou J,. Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol. 2008; 19 (3): 469-76.
25. Smith LA, Bukanov NO, Husson H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006; 17 (10): 2821-31.
26. Xiao Z, Zhang S, Cao L, Qiu N, David V, Quarles LD,. Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. J Biol Chem. 2010; 285 (2): 1177-87.
27. Xiao Z, Zhang S, Mahlios J, et al. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem. 2006; 281 (41): 30884-95.
28. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6 (4): 877-82.
29. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D,. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013; 8 (5): 819-23.
30. Balooch G, Balooch M, Nalla RK,. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005; 102 (52): 18813-8.
31. Alliston T,. TGF-beta regulation of osteoblast differentiation and bone matrix properties. J Musculoskelet Neuronal Interact. 2006; 6 (4): 349-50.
32. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
33. Breen EC, Ignotz RA, McCabe L, Stein JL, Stein GS, Lian JB,. TGF beta alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J Cell Physiol. 1994; 160 (2): 323-35.
34. Zhou S,. TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J Cell Biochem. 2011; 112 (6): 1651-60.
35. Chen G, Deng C,. Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012; 8 (2): 272-88.
36. Zhao L, Hantash BM,. TGF-beta1 regulates differentiation of bone marrow mesenchymal stem cells. Vitam Horm. 2011; 87: 127-41.
37. Filvaroff E, Erlebacher A, Ye J, et al. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development. 1999; 126 (19): 4267-79.
38. Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010; 25 (11): 2419-26.
39. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL,. IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003; 63 (3): 899-07.
40. Duarte ME, Carvalho EF, Cruz EA, Lucena SB, Andress DL,. Cytokine accumulation in osteitis fibrosa of renal osteodystrophy. Braz J Med Biol Res. 2002; 35 (1): 25-9.
41. Tamagaki K, Yuan Q, Ohkawa H, et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant. 2006; 21 (3): 651-9.
42. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
43. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T,. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008; 23 (11): 1712-21.
44. Bivi N, Condon KW, Allen MR, et al. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res. 2012; 27 (2): 374-89.
45. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R,. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
46. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC,. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15 (7): 1943-51.
47. Wallingford JB, Mitchell B,. Strange as it may seem: the many links between Wnt signalling, planar cell polarity, and cilia. Genes Dev. 2011; 25: 201-13.
48. Mundy GR, Bonewald LF,. Role of TGF beta in bone remodeling. Ann NY Acad Sci. 1990; 593: 91-7.
49. Janssens K, ten Dijke P, Janssens S, Van Hul W,. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26 (6): 743-74.
50. Lee SB, Kanasaki K, Kalluri R,. Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population. Kidney Int. 2009; 76 (1): 10-2.
51. Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000; 26 (1): 19-20.
52. Hernandez MV, Peris P, Guanabens N, et al. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family. Calcif Tissue Int. 1997; 61 (1): 48-51.
53. Whyte MP, Totty WG, Novack DV, Zhang X, Wenkert D, Mumm S,. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFbeta1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res. 2011; 26 (5): 920-33.
54. Gebken J, Brenner R, Feydt A, et al. Increased cell surface expression of receptors for transforming growth factor-beta on osteoblasts from patients with osteogenesis imperfecta. Pathobiology. 2000; 68 (3): 106-12.
55. Mohammad KS, Chen CG, Balooch G, et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 2009; 4 (4): e5275.
56. Cicek M, Vrabel A, Sturchio C, et al. TGF-beta inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One. 2011; 6 (3): e17522.
57. Houde N, Chamoux E, Bisson M, Roux S,. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem. 2009; 284 (35): 23397-404.
58. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ,. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res. 2008; 314 (15): 2725-38.
59. Karst M, Gorny G, Galvin RJ, Oursler MJ,. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol. 2004; 200 (1): 99-106.
60. Yasui T, Kadono Y, Nakamura M, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res. 2011; 26 (7): 1447-56.
61. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP,. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. 2011; 34 (10): 801-10.
62. Mundy GR,. The effects of TGF-beta on bone. Ciba Found Symp. 1991; 157: 137-43 discussion 143-51.
63. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC,. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007; 22 (10): 1492-501.
64. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC,. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998; 13 (5): 793-802.
65. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005; 96 (6): 1212-30.
66. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS,. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res. 2001; 16 (10): 1754-64.
67. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37 (2): 148-58.
68. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007; 38 (4): 261-9.
69. Trombetti A, Cortes F, Kaelin A, Morris M, Rizzoli R,. Intranasal calcitonin reducing bone pain in a patient with Camurati-Engelmann disease. Scand J Rheumatol. 2012; 41 (1): 75-7.
70. Jastrzebski S, Kalinowski J, Stolina M, et al. Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res. 2013; 28 (3): 618-26.